Anti Inflammatory News and Research

RSS

Scientists uncover an important link between inflammation and breast cancer stem cells

Scientists at the University of Michigan Comprehensive Cancer Center have uncovered an important link between inflammation and breast cancer stem cells that suggests a new way to target cells that are resistant to current treatments.

4 Jan 2010

BioElectronics set to market its Allay product in Chinese market

BioElectronics Corporation, the maker of inexpensive, disposable, drug-free, anti-inflammatory devices, today announces its entry into one most dynamic and fastest growing economies in the world, the People's Republic of China.

4 Jan 2010

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

InterMune, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review designation for the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

4 Jan 2010

BioElectronics announces product gains in international market; expects significant revenue in 2010

BioElectronics Corp., the maker of inexpensive, disposable, drug-free anti-inflammatory devices, today announces product gains in the international market as well as new international distributor and marketing partnerships. As a result, BioElectronics is expecting significant gains in international markets throughout 2010.

31 Dec 2009

Meda expands collaboration with Etypharm for Axorid

Meda expands the collaboration with the French development company Etypharm for the patented product Axorid. New territories, such as East Europe with Russia and Turkey, are now included in the collaboration. Previously, Meda held commercialization rights in Central and West Europe.

30 Dec 2009

Excess physical activity can lead to foot and ankle problems

Are you one of the millions of Americans who will resolve to exercise more in the New Year? If so, take advice from the American Orthopaedic Foot & Ankle Society (AOFAS) and take it slowly. Too much activity too quickly can cause a multitude of foot and ankle problems including stress fractures, ruptured tendons, or plantar fasciitis.

29 Dec 2009

Aeolus Pharmaceuticals reports financial results for three months and twelve months ended September 30, 2009

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months and twelve months ended September 30, 2009. The Company reported a net loss of $746,000, or $0.02 per share, for the three months ended September 30, 2009 compared to a loss of $1,055,000, or $0.03 per share, for the three months ended September 30, 2008.

28 Dec 2009

Anti-inflammatory coxib medications inhibit aspirin's protective qualities

A new study conducted at Ben-Gurion University of the Negev (BGU) reveals that Celebrex and other anti-inflammatory coxib medications may counter the positive effects of aspirin in preventing blood clots.

24 Dec 2009

Ultrasound-guided cortisone injections, an effective treatment method for gluteus medius tendinopathy

Ultrasound-guided cortisone injections may be an effective treatment method for gluteus medius tendinopathy, a common, painful condition caused by an injury to the tendons in the buttocks that typically affects middle-aged to elderly women and young active individuals, according to a study published in the January issue of the American Journal of Roentgenology.

23 Dec 2009

Viron Therapeutics' three drug candidates granted U.S. patents

Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.

23 Dec 2009

MAA for naproxcinod submitted to EMEA through centralized procedure

NicOx S.A. today announced that a Marketing Authorization Application (MAA) for naproxcinod has been submitted to the European Medicines Agency (EMEA) through the centralized procedure, seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA).

22 Dec 2009

New findings reveal POPG lipid can prevent RSV infection in lungs

Researchers at National Jewish Health have discovered that a naturally occurring lipid in the lung can prevent RSV infection and inhibit spread of the virus after an infection is established. RSV is the major cause of hospitalization for children in the first two years of life, and is increasingly recognized as a dangerous pathogen in adults with chronic lung diseases, the elderly, and immunocompromised individuals. Currently, there is no effective vaccine for the virus.

22 Dec 2009

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.

21 Dec 2009

Swedish agency approves Medivir's Xerclear for treatment of cold sores

The Swedish Medical Products Agency has now approved Xerclear™ for treatment of cold sores. It is the first and only topical treatment that has been demonstrated to prevent the incidence of cold sores and shorten healing-times. Xerclear™ will be available from pharmacies in the first half-year 2010.

21 Dec 2009

ISTA Pharmaceuticals files sNDA for bromfenac ophthalmic solution

ISTA Pharmaceuticals, Inc., today announced the Company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for bromfenac ophthalmic solution dosed once-daily as a treatment for ocular inflammation and pain following cataract surgery.

18 Dec 2009

Prophylactic misuse of NSAIDs cause more harm than good

Athletes' superstitions and rituals can help them get psyched up for contests, but when these rituals involve non-steroidal anti-inflammatory drugs (NSAIDs), which many athletes gobble down before and during events, they could be causing more harm than good.

17 Dec 2009

Diet rich in omega-3 fatty acids linked to improved nervous-system function

The omega-3 essential fatty acids commonly found in fatty fish and algae help animals avoid sensory overload, according to research published by the American Psychological Association.

17 Dec 2009

Pistachios can decrease inflammation and cardiovascular disease

New research published online, December 10, 2009 indicates that bioactive compounds in pistachios, and molecules present in pistachios, have anti-inflammatory properties.

17 Dec 2009

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Anti Inflammatory News and Research

Scientists uncover an important link between inflammation and breast cancer stem cells

BioElectronics set to market its Allay product in Chinese market

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

BioElectronics announces product gains in international market; expects significant revenue in 2010

Meda expands collaboration with Etypharm for Axorid

Excess physical activity can lead to foot and ankle problems

Aeolus Pharmaceuticals reports financial results for three months and twelve months ended September 30, 2009

Anti-inflammatory coxib medications inhibit aspirin's protective qualities

Ultrasound-guided cortisone injections, an effective treatment method for gluteus medius tendinopathy

Viron Therapeutics' three drug candidates granted U.S. patents

MAA for naproxcinod submitted to EMEA through centralized procedure

New findings reveal POPG lipid can prevent RSV infection in lungs

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Swedish agency approves Medivir's Xerclear for treatment of cold sores

ISTA Pharmaceuticals files sNDA for bromfenac ophthalmic solution

Prophylactic misuse of NSAIDs cause more harm than good

Diet rich in omega-3 fatty acids linked to improved nervous-system function

Pistachios can decrease inflammation and cardiovascular disease

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News